Esperion unveils long-awaited data on cholesterol pill's ability to cut cardiovascular risk: #ACC23
NEW ORLEANS — Esperion Therapeutics revealed long-awaited data on its heart pill’s efficacy in cutting severe cardiovascular outcomes, three years after the drug was cleared for use to lower cholesterol levels.
In the company’s CLEAR study of nearly 14,000 patients who are statin intolerant, Esperion’s drug Nexletol cut the combined risk of heart attack, stroke, cardiovascular death or the need for coronary revascularization by 13%, compared with placebo.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
